Clinical trials: Controlled Hypertension
Endothelial Dysfunction, Hyperhomocysteinemia
Effect of L-Arginine and Pycnogenol on Light to Moderate Hypertension and Endothelial Function
The effect of a combination product (Verum ) with L-arginine, Pycnogenol, vitamin K2, R-(+)-alpha-lipoic acid and vitamins B6, B12 and folic acid is investigated in a double blind placebo-controlled cross-over study.
- Conditions
- Endothelial Dysfunction, Hyperhomocysteinemia, Hypertension Grade I, Subgroup "Borderline" (WHO)
- Trial name
- NCT02392767
- Testing
- Verum
- Where
- Germany
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Dr. Loges & Co. GmbH
Uncontrolled Hypertension
A Phase IIIb Study to Investigate the Effect of Baxdrostat in Chinese Participants With Uncontrolled Hypertension.
This is a Phase IIIb, multicentre, randomised, double-blind, placebo-controlled, parallel group study to evaluate the effect of baxdrostat 2mg versus placebo, administered QD orally, on the reduction of ambulatory 24-hour average…
- Trial name
- BaxNoD (NCT07686120)
- Testing
- baxdrostat 2mg
- Where
- 51 sites in China
- Volunteers
- 286 people
- Sponsor
- AstraZeneca
Healthy Adult, Hypertension
A Phase I Single and Multiple Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of HS-10522 in Healthy Chinese Participants and Chinese Participants With Mild Hypertension
The purpose of this study is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple oral doses of HS-10522 in healthy Chinese participants and Chinese participants with…
- Trial name
- NCT07609875
- Testing
- HS-10522
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Open Angle Glaucoma, Ocular Hypertension
Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan
Test ocular hypotensive efficacy and systemic safety of netarsudil 0.01%, 0.02%, 0.04% relative to placebo in subjects with open-angle glaucoma or ocular hypertension in Japan
- Trial name
- NCT03844945
- Testing
- Netarsudil Ophthalmic Solution 0.01%, Netarsudil Ophthalmic Solution 0.02%, Netarsudil Ophthalmic Solution 0.04%
- Where
- 25 sites in Japan
- Volunteers
- 215 people
- Sponsor
- Aerie Pharmaceuticals
Pulmonary Arterial Hypertension
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.
A phase 3, randomized, double-blind, placebo-controlled study to assess safety and efficacy of ambrisentan in subjects with pulmonary arterial hypertension.
- Trial name
- NCT00423202
- Testing
- ambrisentan
- Volunteers
- 186 people
- Sponsor
- Gilead Sciences
Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH)
A Phase 3 Study of Extended-release Tacrolimus in Subjects With Pulmonary Arterial Hypertension and Functional Limitations
This study evaluates the effects of VI-0106 (an extended-release formulation of tacrolimus) in participants with pulmonary arterial hypertension (PAH) who continue to have functional limitations despite being on optimized…
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Arterial Hypertension PAH
- Trial name
- TRANSCEND (NCT07612657)
- Testing
- VI-0106
- Volunteers
- 300 people
- Sponsor
- VIVUS LLC
Healthy Adult Participants
Safety, Tolerability and Pharmacokinetics Study of L608 in Healthy Adults
This is a single ascending dose study of L608 in healthy participants and is being conducted to evaluate the safety of L608 with dose level ranging from 10 μg to 20 μg.
- Trial name
- NCT06429930
- Testing
- L608 Liposomal inhalation suspension
- Where
- New Zealand
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Pharmosa Biopharm Inc.
Pulmonary Hypertension
Efficacy and Safety of Bosentan in Sickle Cell Disease (SCD) Patients With Pulmonary Arterial Hypertension (PAH)
The study will assess the effect of bosentan on pulmonary vascular resistance and exercise capacity in sickle cell disease (SCD) patients diagnosed with pulmonary arterial hypertension.
- Trial name
- NCT00310830
- Testing
- Bosentan
- Volunteers
- 14 people
- Sponsor
- Actelion
Hypertension
Antihypertensive Efficacy and Safety of Approved Drugs in Japanese Patients With Essential Hypertension (Banyu Study)(0954A-302)
The purpose of this study is to evaluate antihypertensive (lowering blood pressure) effectiveness of three combinations of approved study drugs compared to both study drugs being given alone.
- Trial name
- NCT00092209
- Testing
- MK0954A, hydrochlorothiazide (+) losartan potassium
- Volunteers
- 840 people
- Sponsor
- Organon and Co
Healthy, Diabetes
Safety for 24 Weeks Intake of Korean Red Ginseng in Adults
Korean Red Ginseng appears to adverse events in adults taking 24 weeks Placebo and comparative assessment. And exploratory as Korean Red Ginseng blood sugar control, reduce body fat, URTI prevention, cardiovascular risk, renal…
- Conditions
- Healthy, Diabetes, Hypertension, Hyperlipidemia
- Trial name
- NCT02428998
- Testing
- Korean Red Ginseng
- Where
- South Korea
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Korea Ginseng Corporation
Hypertension
Safety and Effect Study of SHR0532 (Drug Code) Tablets in Patients With Mild Hypertension
The study is being conducted to evaluate the safety and efficacy and Pharmacokinetics/Pharmacodynamics of SHR0532 in subjects with mild hypertension for 4 weeks.
- Trial name
- NCT03971929
- Testing
- SHR0532, Hydrochlorothiazide 25 mg
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Non-operable Chronic Thromboembolic Pulmonary Hypertension
Efficacy and Tolerability of Subcutaneously Administered Treprostinil Sodium in Patients With Severe (Non-operable) Chronic Thromboembolic Pulmonary Hypertension (CTREPH)
The primary purpose of this study is to determine the effect on six-minute walking test (6MWT) distance after 24 weeks treatment with subcutaneous (SC) Treprostinil Sodium in patients with Severe (inoperable) Chronic…
- Trial name
- CTREPH (NCT01416636)
- Testing
- Treprostinil sodium
- Where
- 6 sites in Austria, Czechia and 2 more
- Volunteers
- 105 people
- Sponsor
- SciPharm SàRL
Glaucomas, Pterygium
Ologen (OculusGen)-Glaucoma and Pterygium Historical Control Study in China Zhong-Shan Hospital
The purpose of this study is to determine whether the OculusGen Collagen Matrix are effective and safe to implant as an aid of glaucoma surgery.
- Trial name
- NCT00320957
- Testing
- OculusGen Biodegradable Collagen Matrix Implant
- Where
- China
- Volunteers
- 61 people
- Sponsor
- Pro Top & Mediking Company Limited
Chronic Kidney Disease, Arterial Hypertension
A Study to Learn About the Safety of BAY3283142 in People With Mild to Moderate High Blood Pressure
In this study, researchers want to learn about the safety of BAY3283142 after a single dose and multiple doses in participants with mild to moderate high blood pressure.
- Trial name
- NCT06428825
- Testing
- BAY3283142
- Where
- 2 sites in Germany
- Volunteers
- 75 people
- Sponsor
- Bayer
Uncontrolled Hypertension
A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Uncontrolled Hypertension
This is a multicenter, randomized, double-blind, placebo-controlled phase II study designed to explore the efficacy and safety of different doses of SAL0140 in uncontrolled hypertension.
- Trial name
- NCT07654140
- Testing
- SAL0140
- Where
- China
- Volunteers
- 252 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Hypertension
A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen
A Phase 2 trial to evaluate the blood pressure-lowering effect of lorundrostat an aldosterone synthase inhibitor (ASI), administered as an add-on to a standardized anti-hypertensive (AHT) medication regimen, in subjects with…
- Trial name
- NCT05769608
- Testing
- lorundrostat Dose 1, lorundrostat Dose 2
- Where
- 104 sites in United States
- Volunteers
- 285 people
- Sponsor
- Mineralys Therapeutics Inc.
Chronic Kidney Disease, Diabetic Kidney Disease
A Trial to Learn More About How BAY2327949 Works and How Safe it is in Patients Whose Kidneys Are Damaged Due to High Blood Sugar Levels or High Blood Pressures, and With a Further Disease of the Heart or the Blood Vessels.
In people with type 2 diabetes (T2D), the body makes insulin, but cannot use it well. This results in high blood sugar levels causing damage to the blood vessels inside the kidneys.
- Trial name
- ASSESS-CKD (NCT04661917)
- Testing
- BAY2327949
- Where
- 36 sites in Austria, Denmark and 5 more
- Sponsor
- Bayer
High Blood Pressure
A Clinical Study With Aliskiren Alone or in Combination Therapy With Diuretic Hctz in Venezuelan Hypertensive Patients.
This is an open-label, not controlled, sequential, dose escalation study of 16 weeks' duration. The study is composed of two periods: a 0-2 week optional wash-out period depending on previous antihypertensive treatment(s)…
- Trial name
- ANDROMEDA (NCT01056731)
- Testing
- Aliskiren and HCTZ
- Where
- 7 sites in Venezuela
- Volunteers
- 253 people
- Sponsor
- Novartis
Pulmonary Arterial Hypertension
Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy
This is an international, multicenter, randomized, double-blind, placebo-controlled, event driven study in subjects with pulmonary arterial hypertension.
- Trial name
- FREEDOM-EV (NCT01560624)
- Testing
- Treprostinil Diolamine
- Where
- 155 sites in United States, Argentina and 21 more
- Volunteers
- 690 people
- Sponsor
- United Therapeutics
Ocular Hypertension
An Open-Label Study of an Ophthalmic Solution to Reduce Intraocular Pressure in Patients With Ocular Hypertension
The purpose of this study is to determine the safety and tolerability of topical C-KAD Ophthalmic Solution in reducing intraocular pressure in patients with ocular hypertension.
- Trial name
- NCT00825396
- Testing
- C-KAD Ophthalmic Solution
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Chakshu Research, Inc.